Table 2.
Discriminatory accuracy of serum BD-tau and other serum biomarkers to separate Alzheimer’s disease from specific non-Alzheimer’s disease disorders
| Serum BD-tau | Serum NfL | |
|---|---|---|
| Group comparison | AUC (95% confidence interval) | |
| AD versus avPPA | 88.9% (81.1–96.6%) | 62.2% (50.5–74%) |
| AD versus avPPA/GRN | 99.6% (98.7–100%) | 94% (88.2–99.7%) |
| AD versus svPPA | 87.3% (77.4–97.1%) | 50.9% (36.5–65.3%) |
| AD versus bvFTD | 93.2% (89.4–97%) | 51.2% (42.2–60.25%) |
| AD versus bvFTD/GRN | 81.6% (63.7–99.5%) | 94.4% (89–99.8%) |
| AD versus CBS | 83.8% (75.2–92.4%) | 51.5% (39.4–63.6%) |
| AD versus PSP | 77.8% (65.8–90.5%) | 58.9% (45.4–72.3%) |
AD = Alzheimer’s disease; avPPA = agrammatic variant primary progressive aphasia; avPPA/GRN = agrammatic variant primary progressive aphasia with progranulin mutation; bvFTD = behavioural frontotemporal dementia; bvFTD/GRN = behavioural frontotemporal dementia with progranulin mutation; CBS = corticobasal syndrome; PSP = progressive supranuclear palsy; svPPA = semantic variant primary progressive aphasia.